Trial Profile
Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jul 2019
Price :
$35
*
At a glance
- Drugs Almorexant (Primary) ; Zolpidem (Primary)
- Indications Sleep disorders
- Focus Pharmacodynamics
- 19 Jun 2013 Planned end date changed from 1 Feb 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 13 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 May 2011 Actual initiation date (May 2011) added as reported by ClinicalTrials.gov.